吉非替尼治疗晚期肺腺癌25例临床观察

目的观察吉非替尼治疗晚期肺腺癌的近期疗效及毒副反应。方法 25例经放疗和化疗方案为"TP"或"GP"治疗无效或失败的肺腺癌患者。吉非替尼250 mg次/,口服,1次/d;服用至病情进展或出现不可耐受的毒副反应。结果本组25例患者均可评价疗效,完全缓解0例,部分缓解6例,稳定10例,进展9例,有效率24%,疾病控制率64%,中位生存期5.2个月(1~18个月),1年生存率52%;主要毒副反应是皮疹、皮肤瘙痒、皮肤干燥、腹泻和恶心,多为Ⅰ~Ⅱ度。结论吉非替尼治疗晚期肺腺癌有一定疗效,安全易耐受,无明显毒副反应。

Clinical Observation on Gefitinib in the Treatment of 25 Patients with Advanced Pulmonary Adenocarcinoma

Objective To evaluate the efficacy and toxicities of gefitinib in the treatment of patients with advanced pulmonary adenocarcinoma.Methods The 25 patients with advanced pulmonary adenocarcinoma who failed prior to chemotherapy and radiotherapy received the gefitinib treatment(250 mg/time,oral,1 time/d) until disease progression or intolerable toxicities.Results In the 25 patients,the 0 patient got CR,the 6 patients PR,the 10 patients SD,and the 9 patients PD.The total response rate was 24%,and the disease control rate was 64%.The median survival time was 5.2 months(1-18 months).The one year survival rate was 52%.The main toxicities of gefitinib were skin rash,itch of skin,skin dry,diarrhea and nausea,they were mostly degreeⅠ-Ⅱ.Conclusion Gefitinib is effective and safe in the treatment of the patients with advanced pulmonary adenocarcinoma.